A study to find out vitamin D effect on hormones cortisol, estrogen and testosterone and its impact on primary open angle glaucoma

Effect of vitamin D supplementation on serum levels of cortisol, estrogen and testosterone in patients of primary open angle glaucoma - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069692

Enrollment

120

Registered

2024-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

Intervention1: Vitamin D3: dose:60000 IU frequency: Once a week route of administration: oral total duration: 12 weeks Control Intervention1: Placebo: dose:60000 IU frequency: Once a week route of a

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Primary open angle glaucoma

Exclusion criteria

Exclusion criteria: 1. Patients receiving vit D and calcium supplements 2. Patients taking any other medication that could change vit D metabolism such as Phenytoin or Rifampin 3. Patients taking any medication that could change cortisol metabolism such as steroids, ketoconazole or mitotane. 4. Patients taking Hormone Replacement Therapy 5. Patients with very low and sufficient vit D levels

Design outcomes

Primary

Measure	Time frame
1. To study the effect of vit D supplementation on serum cortisol levels in patients of POAG 2. To study the effect of vit D supplementation on serum estrogen levels in patients of POAG 3. To study the effect of vit D supplementation on serum testosterone levels in patients of POAGTimepoint: 12 weeks	—

Secondary

Measure	Time frame
1. To study the effect of vit D supplementation on control of intraocular pressure in patients of POAG 2. To compare the levels of serum cortisol in diabetic and non-diabetic patients of POAG 3. To compare the levels of serum estrogen in diabetic and non-diabetic patients of POAG 4. To compare the levels of serum testosterone in diabetic and non-diabetic patients of POAGTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactKavitha G Pradeep

Institute of Ophthalmology,JNMCH,AMU

s_zrab@yahoo.com9837003911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026